We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions In Patients Receiving Interferon Beta Therapy
Multiple Sclerosis Biogen Idec Inc. (Nasdaq: BIIB) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta therapy in patients with active relapsing multiple sclerosis (MS). These data will be presented tomorrow at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic. [click link for full article]
Custom Search
